LLY

769.87

+0.76%↑

JNJ

155.03

+1.03%↑

ABBV

189.89

+1.42%↑

NVO

74.74

+3.06%↑

UNH

303.11

+2.59%↑

LLY

769.87

+0.76%↑

JNJ

155.03

+1.03%↑

ABBV

189.89

+1.42%↑

NVO

74.74

+3.06%↑

UNH

303.11

+2.59%↑

LLY

769.87

+0.76%↑

JNJ

155.03

+1.03%↑

ABBV

189.89

+1.42%↑

NVO

74.74

+3.06%↑

UNH

303.11

+2.59%↑

LLY

769.87

+0.76%↑

JNJ

155.03

+1.03%↑

ABBV

189.89

+1.42%↑

NVO

74.74

+3.06%↑

UNH

303.11

+2.59%↑

LLY

769.87

+0.76%↑

JNJ

155.03

+1.03%↑

ABBV

189.89

+1.42%↑

NVO

74.74

+3.06%↑

UNH

303.11

+2.59%↑

Search

Aldeyra Therapeutics Inc

Suletud

2.65 8.16

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

2.58

Max

2.66

Põhinäitajad

By Trading Economics

Sissetulek

5.9M

-9.9M

Aktsiakasum

-0.17

Kasumimarginaal

-6,465.066

Töötajad

8

EBITDA

5.9M

-9.4M

Soovitused

By TipRanks

Soovitused

Tugev "osta" hinnang

12 kuu keskmine prognoos

+280.82% upside

Dividendid

By Dow Jones

Järgmine tulemuste avaldamine

30. juuli 2025

Turustatistika

By TradingEconomics

Turukapital

-5M

127M

Eelmine avamishind

-5.51

Eelmine sulgemishind

2.65

Tehniline skoor

By Trading Central

Kindlus

Very Strong Bearish Evidence

Aldeyra Therapeutics Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

3. apr 2025, 22:40 UTC

Suurimad hinnamuutused turgudel

Aldeyra Shares Fall on FDA Complete Response Letter for Dry Eye Disease Drug

18. nov 2024, 20:20 UTC

Suurimad hinnamuutused turgudel

Aldeyra Therapeutics Shares Up, FDA to Review New Drug Application

Võrdlus sarnastega

Hinnamuutus

Aldeyra Therapeutics Inc Prognoos

Hinnasiht

By TipRanks

280.82% tõus

12 kuu keskmine prognoos

Keskmine 9.33 USD  280.82%

Kõrge 11 USD

Madal 6 USD

Põhineb 6 Wall Streeti analüütiku instrumendi Aldeyra Therapeutics Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Tugev "osta" hinnang

6 ratings

6

Osta

0

Hoia

0

Müü

Tehniline skoor

By Trading Central

1.9 / 2.65Toetus ja vastupanu

Lühikene perspektiiv

Very Strong Bearish Evidence

Keskpikk perspektiiv

Very Strong Bearish Evidence

Pikk perspektiiv

Strong Bearish Evidence

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

$

Ettevõttest Aldeyra Therapeutics Inc

Aldeyra Therapeutics, Inc., a biotechnology company, develops and commercializes medicines for immune-mediated diseases. Its lead product candidate is reproxalap, a reactive aldehyde species (RASP)modulator, which is in Phase III clinical trial for the treatment of dry eye diseases. The company also develops ADX-629, an orally administered RASP modulator for treatment of COVID-19, atopic asthma, psoriasis, and alcohol intoxication; and ADX-2191, a dihydrofolate reductase inhibitor for the treatment retinitis pigmentosa, as well as rare retinal diseases characterized by inflammation and vision loss. In addition, it develops ADX-246 in systemic immune-mediated disease; and ADX-248 in geographic atrophy. The company was formerly known as Aldexa Therapeutics, Inc. and changed its name to Aldeyra Therapeutics, Inc. in March 2014. Aldeyra Therapeutics, Inc. was incorporated in 2004 and is based in Lexington, Massachusetts.